Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Surrozen Inc(SRZN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SRZN
09/25/2026: SRZN (1-star) is currently NOT-A-BUY. Pass it for now.
Surrozen Inc is a clinical-stage biotechnology company that leverages proprietary platforms to modulate the Wnt pathway for tissue regeneration. The company’s primary strength lies in its highly specialized scientific expertise and a focused pipeline targeting conditions like inflammatory bowel disease. Its investment story centers on the potential for its clinical-stage assets to validate a previously 'undruggable' pathway, though the company remains in a high-risk, pre-commercial stage. Key risks include significant execution challenges, clinical failure, and the need for frequent capital raises. This stock is best suited for growth-oriented investors who can tolerate high volatility, with investors urged to monitor upcoming clinical data readouts as the primary catalysts.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-growth potential if clinical trials succeed, but the risk profile is extremely high. |
| Momentum investor | Weak fit | Momentum interest is typically inconsistent unless driven by major, positive clinical trial catalysts. |
| Value investor | Weak fit | As a loss-making pre-commercial company, standard value metrics like P/E ratios are not applicable. |
| Dividend investor | Weak fit | The company does not pay a dividend and focuses on cash preservation for R&D. |
| Low-risk investor | Weak fit | The extreme volatility and binary nature of clinical outcomes are unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks are highly sensitive to clinical data, leading to sharp price swings. |
| Valuation risk | High | Valuations are highly speculative and depend entirely on the future success of clinical assets. |
| Competition risk (Biotech) | High | The company competes with massive pharmaceutical firms with superior financial resources. |
| Business quality | Medium | The science is robust, but the business is in the early stages with no revenue-generating products. |
| Dividend income | Low / none | The company is not an income-generating investment. |
| Execution risk | High | Successful development and regulatory approval are inherently uncertain and difficult to execute. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -51.28% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 395.86M USD | Price to earnings Ratio - | 1Y Target Price 46.4 |
Price to earnings Ratio - | 1Y Target Price 46.4 | ||
Volume (30-day avg) 614.1K shares | Beta 0.56 | 52 Weeks Range 11.39 - 37.83 | Updated Date 09/25/2026 |
52 Weeks Range 11.39 - 37.83 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -83.49 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Research & Development | Collaborations, licensing agreements, and potential future product sales. | The company currently makes very little money and is burning cash to build its future products. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 94.21M | Price to Sales(TTM) 34.39 |
Enterprise Value 94.21M | Price to Sales(TTM) 34.39 | ||
Enterprise Value to Revenue 8.18 | Enterprise Value to EBITDA 0.71 | Shares Outstanding 11.75M | Shares Floating 4.62M |
Shares Outstanding 11.75M | Shares Floating 4.62M | ||
Percent Insiders 3.14 | Percent Institutions 104.86 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Surrozen Inc
Exchange NASDAQ | Headquarters South San Francisco, CA, United States | ||
IPO Launch date 2021-01-11 | CEO, President & Director Mr. Craig C. Parker M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 44 | Website https://www.surrozen.com |
Full time employees 44 | Website https://www.surrozen.com | ||
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.